2. Search Result
Search Result
Results for "

DR5 Activator

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18377
    Bioymifi

    DR5 Activator

    		 TNF Receptor Apoptosis Cancer
    Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
    Bioymifi
  • HY-P99260
    Conatumumab

    AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody

    		 TNF Receptor Cancer
    Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .
    Conatumumab
  • HY-165537
    Siphonaxanthin

    		FGFR Apoptosis Bcl-2 Family Caspase Inflammation/Immunology Cancer
    Siphonaxanthin is a keto-carotenoid found in green algae. Siphonaxanthin targets death receptor 5 (DR5) and induces apoptosis in cancer cells. Siphonaxanthin upregulates the expression of DR5, decreases the expression of Bcl-2, and activates caspase-3 in human leukemia HL-60 cells. Siphonaxanthin is an inhibitor of fibroblast growth factor receptor-1 (FGFR-1) signaling transduction in vascular endothelial cells. Siphonaxanthin inhibits the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), as well as the outgrowth of microvessels in the rat aortic ring. Siphonaxanthin can also inhibit the translocation of the high-affinity IgE receptor (FcεRI) to lipid rafts in mast cells, acting as an anti-inflammatory agent. Siphonaxanthin is promising for research of diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis .
    Siphonaxanthin
  • HY-163801
    Nurr1 agonist 9

    		Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC50 of 0.090 µM and a Kd of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC50=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC50=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable .
    Nurr1 agonist 9
  • HY-173025
    Nurr1 agonist 12

    		Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 12 (Compound 37) is the agonist for nuclear receptor-associated protein 1 (Nurr1) that activates the transcriptional activity of Nurr1 with an EC50 of 0.06 μM. Nurr1 agonist 12 activates the human response elements NBRE, NurRE, and DR5 with EC50 of 0.07 μM, 0.027 μM, and 0.014 μM, respectively. Nurr1 agonist 12 induces the expression of Nurr1-regulated neurotrophic genes, such as tyrosine hydroxylase (TH), SOD1/2, BDNF, Sestrin 3, and BIRC5 (Survivin). Nurr1 agonist 12 exhibits neuroprotective efficacy against Paraquat-induced neurotoxicity .
    Nurr1 agonist 12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: